Supplemental material
Journal of Medical Economics
Volume 27, 2024 - Issue 1
Open access
487
Views
1
CrossRef citations to date
0
Altmetric
Oncology
Challenges, considerations, and approaches for developing a cost-effectiveness model for the adjuvant treatment of muscle-invasive urothelial carcinoma: with a spotlight on nivolumab versus placebo
Siguroli Teitssona Bristol Myers Squibb, Uxbridge, UKCorrespondence[email protected]
https://orcid.org/0009-0001-7378-1675
, https://orcid.org/0009-0001-7378-1675
Thor-Henrik Brodtkorbb RTI Health Solutions, Ljungskile, Swedenhttps://orcid.org/0000-0002-9899-233X
, Murat Kurtc Bristol Myers Squibb, Princeton, NJ, USA
, Miraj Y. Patelc Bristol Myers Squibb, Princeton, NJ, USAhttps://orcid.org/0000-0002-3543-1420
, Tayla Porettac Bristol Myers Squibb, Princeton, NJ, USA
, Christopher Knightd RTI Health Solutions, Manchester, UK
, Farzam Kamgarb RTI Health Solutions, Ljungskile, Sweden
& Stephen Palmere Centre for Health Economics, University of York, York, UKhttps://orcid.org/0000-0002-7268-2560
show all
Pages 473-481
|
Received 21 Dec 2023, Accepted 14 Feb 2024, Published online: 25 Mar 2024
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.